Funded Biotechnology Startups in Canada
The 50 most recent funding rounds among Canadian biotechnology companies span a wide range in both size and stage, from a $133M Series A raised by Reunion…
The 50 most recent funding rounds among Canadian biotechnology companies span a wide range in both size and stage, from a $133M Series A raised by Reunion Neuroscience in Toronto in September 2025 to sub-$100K pre-seed checks in smaller markets. Vancouver and Toronto together account for the majority of activity, with Montreal and its surrounding Quebec cities forming a secondary cluster.
Most rounds in this set carry a "Series Unknown" label — many below $1M — suggesting heavy reliance on public market financings and smaller venture instruments prevalent in Canadian biotech. The two largest disclosed rounds, Reunion Neuroscience ($133M) and Aspect Biosystems ($115M, Vancouver, Series B, January 2025), stand out sharply against a median that sits well under $5M. Halifax produced two rounds — ABK Biomedical's $35M Series D and 3D BioFibR's $3M Seed — signaling emerging activity outside the traditional Ontario and BC hubs.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among recently funded Canadian biotech companies?
Reunion Neuroscience raised $133M in a Series A in Toronto in September 2025, and Aspect Biosystems closed a $115M Series B in Vancouver in January 2025 — the two largest by a wide margin. ABK Biomedical's $35M Series D (Halifax, October 2025) and Borealis Biosciences' $30M Series A (Vancouver, December 2024) round out the top four disclosed rounds in this set.
Which cities account for the most funded biotech companies in this data?
Toronto is the most represented city, with at least 12 companies including Reunion Neuroscience, ProteinQure, and Paradox Immunotherapeutics. Vancouver follows with roughly 10 entries including Aspect Biosystems and Borealis Biosciences, while Montreal, Laval, and Quebec City together contribute around eight Quebec-based companies.
What funding stages appear most often in this dataset?
The majority of rounds carry a 'Series Unknown' designation, a pattern common among Canadian public-market biotech companies that use convertible instruments or bought-deal financings rather than traditional VC structures. Among labeled stages, Seed appears eight times — including Augmenta AI ($10M) and Avitia ($5M) — and Series A four times.
Is there a recognizable cluster of neuroscience or CNS-focused companies?
Several companies in the set target the CNS and psychedelic therapy space: Reunion Neuroscience ($133M Series A, Toronto), ProMIS Neurosciences ($7M, Toronto), Synucure Therapeutics ($3M Seed, Montreal), Awakn Life Sciences ($540K, Toronto), and Psyence Biomedical ($1M, Toronto). The cluster spans neurodegeneration, alpha-synuclein targeting, and psychedelic-assisted treatments.
How small are the smallest rounds, and what does the size distribution look like overall?
A meaningful portion of rounds fall below $500K — including Dispersa ($70K, Laval), AgroGene Solutions ($30K), ME Therapeutics ($100K), ZYUS ($180K), and Zamplo ($150K) — and several additional rounds are undisclosed. The distribution is heavily right-skewed: a handful of institutional rounds above $30M coexist with dozens of micro-financings, pulling the typical deal size well under $5M.
Are there funded biotech companies outside Toronto and Vancouver?
Yes. Halifax contributed two rounds — ABK Biomedical ($35M Series D) and 3D BioFibR ($3M Seed). Alberta-based companies include Oncolytics Biotech ($20M, Calgary), Entos Pharmaceuticals ($1M, Edmonton), and Xortx Therapeutics ($3M, Calgary). Charlottetown's Pegasus Biotech ($2M) and Saskatoon's ZYUS ($180K) show activity in Atlantic and Prairie provinces as well.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.